` SOBI (Swedish Orphan Biovitrum AB (publ)) vs OMX Stockholm 30 Comparison - Alpha Spread

SOBI
vs
OMX Stockholm 30

Over the past 12 months, SOBI has outperformed OMX Stockholm 30, delivering a return of 3% compared to the OMX Stockholm 30's 5% drop.

Stocks Performance
SOBI vs OMX Stockholm 30

Loading

Performance Gap
SOBI vs OMX Stockholm 30

Loading
SOBI
OMX Stockholm 30
Difference

Performance By Year
SOBI vs OMX Stockholm 30

Loading
SOBI
OMX Stockholm 30
Add Stock

Competitors Performance
Swedish Orphan Biovitrum AB (publ) vs Peers

OMX Stockholm 30
SOBI
ABBV
AMGN
GILD
VRTX
Add Stock

Swedish Orphan Biovitrum AB (publ)
Glance View

Economic Moat
Narrow
Market Cap
90.1B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments. Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.

SOBI Intrinsic Value
422.95 SEK
Undervaluation 38%
Intrinsic Value
Price
Back to Top